Fair Value Measurements (Narrative) (Detail) (USD $) In Thousands, unless otherwise specified	1 Months Ended	3 Months Ended
	Mar. 31, 2011	Sep. 30, 2012		Sep. 30, 2011	Jun. 30, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign currency contracts outstanding, notional amount		$ 73,346
Unrealized gains (losses) on hedging activities		61		439
Interest rate swap designated as a cash flow hedge, notional amount	20,000
Interest rate swap designated as a cash flow hedge, expiration date	Dec. 31, 2015
Unrealized loss on interest rate swap		432
Contingent consideration at fair value		1,841	[1]		1,779	[2]
Rising Pharmaceuticals Inc. [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration at fair value		$ 1,841			$ 1,779

[1] Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2012.

[2] Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2012.